122 related articles for article (PubMed ID: 11888888)
1. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.
Bauerschmitz GJ; Lam JT; Kanerva A; Suzuki K; Nettelbeck DM; Dmitriev I; Krasnykh V; Mikheeva GV; Barnes MN; Alvarez RD; Dall P; Alemany R; Curiel DT; Hemminki A
Cancer Res; 2002 Mar; 62(5):1266-70. PubMed ID: 11888888
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer.
Bauerschmitz GJ; Kanerva A; Wang M; Herrmann I; Shaw DR; Strong TV; Desmond R; Rein DT; Dall P; Curiel DT; Hemminki A
Int J Cancer; 2004 Aug; 111(2):303-9. PubMed ID: 15197787
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.
Lamfers ML; Idema S; Bosscher L; Heukelom S; Moeniralm S; van der Meulen-Muileman IH; Overmeer RM; van der Valk P; van Beusechem VW; Gerritsen WR; Vandertop WP; Dirven CM
Clin Cancer Res; 2007 Dec; 13(24):7451-8. PubMed ID: 18094429
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
5. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
7. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
[TBL] [Abstract][Full Text] [Related]
8. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids.
Lam JT; Bauerschmitz GJ; Kanerva A; Barker SD; Straughn JM; Wang M; Barnes MN; Blackwell JL; Siegal GP; Alvarez RD; Curiel DT; Hemminki A
Cancer Gene Ther; 2003 May; 10(5):377-87. PubMed ID: 12719707
[TBL] [Abstract][Full Text] [Related]
9. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy.
Wu H; Han T; Lam JT; Leath CA; Dmitriev I; Kashentseva E; Barnes MN; Alvarez RD; Curiel DT
Gene Ther; 2004 May; 11(10):874-8. PubMed ID: 14999229
[TBL] [Abstract][Full Text] [Related]
11. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
[TBL] [Abstract][Full Text] [Related]
12. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
[TBL] [Abstract][Full Text] [Related]
13. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
Witlox AM; Van Beusechem VW; Molenaar B; Bras H; Schaap GR; Alemany R; Curiel DT; Pinedo HM; Wuisman PI; Gerritsen WR
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):61-7. PubMed ID: 14734452
[TBL] [Abstract][Full Text] [Related]
14. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.
Kanerva A; Zinn KR; Chaudhuri TR; Lam JT; Suzuki K; Uil TG; Hakkarainen T; Bauerschmitz GJ; Wang M; Liu B; Cao Z; Alvarez RD; Curiel DT; Hemminki A
Mol Ther; 2003 Sep; 8(3):449-58. PubMed ID: 12946318
[TBL] [Abstract][Full Text] [Related]
15. Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor.
Murugesan SR; Akiyama M; Einfeld DA; Wickham TJ; King CR
Int J Oncol; 2007 Oct; 31(4):813-22. PubMed ID: 17786312
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.
Kanerva A; Wang M; Bauerschmitz GJ; Lam JT; Desmond RA; Bhoola SM; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
Mol Ther; 2002 Jun; 5(6):695-704. PubMed ID: 12027553
[TBL] [Abstract][Full Text] [Related]
17. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
[TBL] [Abstract][Full Text] [Related]
18. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
19. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
20. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches.
Vanderkwaak TJ; Wang M; Gómez-Navarro J; Rancourt C; Dmitriev I; Krasnykh V; Barnes M; Siegal GP; Alvarez R; Curiel DT
Gynecol Oncol; 1999 Aug; 74(2):227-34. PubMed ID: 10419736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
